Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:56:47.096Z.
Calculation as of: 2026-10-06T14:56:47.096Z.
Quote observation: 2026-10-06T14:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
PE RATIO
N/A
Market Cap
$2.00B
PE Ratio
14.96
TTM Avg
29.48
3Y Avg
184.64
5Y Avg
184.64
Market Cap
$2.01B
PE Ratio
6.83
TTM Avg
15.39
3Y Avg
40.25
5Y Avg
40.25
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.96B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.97B | N/A | 1.02 | 1.02 | 39.76 |
| Immunome, Inc. (IMNM)vs › | $1.94B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 14.96 | 29.48 | 184.64 | 184.64 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | N/A | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 6.83 | 15.39 | 40.25 | 40.25 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 7.63 | 7.63 | 7.63 |
| Azenta, Inc. (AZTA)vs › | $1.89B | N/A | 61.77 | 49.90 | 40.42 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 37.72 | 35.65 | 35.65 | 327.33 |
| Alvotech (ALVO)vs › | $2.04B | N/A | 33.55 | 33.55 | 33.55 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$66.55
Forward EPS (Est.)
$-1.20
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
